Display Settings:

Format
Sort by

Send to:

Choose Destination

Results: 4

1.

Activating alleles of JAK3 in acute megakaryoblastic leukemia.

Walters DK, Mercher T, Gu TL, O'Hare T, Tyner JW, Loriaux M, Goss VL, Lee KA, Eide CA, Wong MJ, Stoffregen EP, McGreevey L, Nardone J, Moore SA, Crispino J, Boggon TJ, Heinrich MC, Deininger MW, Polakiewicz RD, Gilliland DG, Druker BJ.

Cancer Cell. 2006 Jul;10(1):65-75.

PMID:
16843266
[PubMed - indexed for MEDLINE]
Free Article
2.

Mutated tyrosine kinases as therapeutic targets in myeloid leukemias.

Sattler M, Scheijen B, Weisberg E, Griffin JD.

Adv Exp Med Biol. 2003;532:121-40. Review.

PMID:
12908554
[PubMed - indexed for MEDLINE]
3.

JAK protein kinase inhibitors.

Thompson JE.

Drug News Perspect. 2005 Jun;18(5):305-10. Review.

PMID:
16193102
[PubMed - indexed for MEDLINE]
4.

JAK3: a two-faced player in hematological disorders.

Cornejo MG, Boggon TJ, Mercher T.

Int J Biochem Cell Biol. 2009 Dec;41(12):2376-9. doi: 10.1016/j.biocel.2009.09.004. Epub 2009 Sep 9. Review.

PMID:
19747563
[PubMed - indexed for MEDLINE]
Free PMC Article

Display Settings:

Format
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk